Conestoga Capital Reports Balchem Growth Amid Gulf War Risks

Conestoga Capital Advisors reported that Balchem Corporation achieved 8% sales growth in the first quarter of 2026, according to the asset manager's second-quarter investor letter. Despite this growth and strong execution in niche markets, Balchem's stock underperformed as investors reacted to potential cost increases associated with the war in the Gulf.

Conestoga maintains its investment thesis for the specialty chemicals company, citing a history of consistent execution. The firm's broader Small Cap Composite returned 14.32% net-of-fees for the quarter.

This return lagged behind the Russell 2000 Growth Index, which gained 25.7%. Conestoga attributed this gap to a market shift where investors favored high-beta AI and semiconductor stocks over high-quality growth businesses.